Galectin Therapeutics (GALT) Equity Income (2014)
Galectin Therapeutics (GALT) recorded quarterly Equity Income of -$10000.0 in Q4 2014, up 81.13% quarter-over-quarter from -$53000.0 in Q3 2014.
Galectin Therapeutics (GALT) Equity Income (2014) Analysis & Trends
Galectin Therapeutics' Equity Income history runs 1 years deep, the most recent figure standing at -$10000.0 for Q4 2014.
- In Q4 2014, Equity Income changed N/A year-over-year to -$10000.0; the TTM figure through Dec 2014 stood at -$400000.0 (changed N/A YoY), while the FY2014 annual figure was -$400000.0, changed N/A from the prior year.
- Equity Income was -$10000.0 for Q4 2014 at Galectin Therapeutics, up from -$53000.0 in the prior quarter.
- In the past five years, Equity Income ranged from a high of -$10000.0 in Q4 2014 to a low of -$270000.0 in Q1 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Galectin Therapeutics | 185.83 Mn | 171.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | -10,000.00 |
| Sep 30, 2014 | -53,000.00 |
| Jun 30, 2014 | -67,000.00 |
| Mar 31, 2014 | -270,000.00 |